Musculoskeletal Focus Target the musculoskeletal implant market where the company projects a $1B U.S. opportunity, leveraging their biocellulose biomaterial and drug-delivery capabilities to position Xylos as a specialty supplier for surgical implants and related devices.

Biomaterial Differentiator Highlight the unique biocellulose technology and its demonstrated safety, versatility, and potential across multiple medical indications to differentiate offerings from competitors and support value-based selling with clinical stakeholders.

Clinical & Drug Delivery Shop for partnerships or pilot opportunities that combine tissue repair solutions with localized drug delivery properties, appealing to hospitals and orthopedic centers seeking advanced therapeutics and reduced revision rates.

Early-Stage Growth Position as an emerging medical device innovator with high-growth potential and a lean team, targeting investors and strategic partners who fund early-stage biomaterial platforms and assist in scaling manufacturing and commercialization.

Low Revenue, High Potential Leverage the current revenue range to pursue channel partnerships, contract development and manufacturing, and government or academic grants for R&D to accelerate product validation, regulatory milestones, and market entry.